- Home
- LIXT vs RNAZ Comparison
LIXT vs RNAZ Comparison
Compare LIXT & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- RNAZ
- Stock Information
- Founded
- LIXT 2005
- RNAZ 2016
- Country
- LIXT United States
- RNAZ United States
- Employees
- LIXT N/A
- RNAZ N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- RNAZ Health Care
- Exchange
- LIXT Nasdaq
- RNAZ Nasdaq
- Market Cap
- LIXT 4.1M
- RNAZ 4.9M
- IPO Year
- LIXT N/A
- RNAZ 2021
- Fundamental
- Price
- LIXT $2.33
- RNAZ $3.35
- Analyst Decision
- LIXT
- RNAZ Strong Buy
- Analyst Count
- LIXT 0
- RNAZ 1
- Target Price
- LIXT N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- LIXT 18.9K
- RNAZ 143.7K
- Earning Date
- LIXT 11-12-2024
- RNAZ 11-14-2024
- Dividend Yield
- LIXT N/A
- RNAZ N/A
- EPS Growth
- LIXT N/A
- RNAZ N/A
- EPS
- LIXT N/A
- RNAZ N/A
- Revenue
- LIXT N/A
- RNAZ N/A
- Revenue This Year
- LIXT N/A
- RNAZ N/A
- Revenue Next Year
- LIXT N/A
- RNAZ N/A
- P/E Ratio
- LIXT N/A
- RNAZ N/A
- Revenue Growth
- LIXT N/A
- RNAZ N/A
- 52 Week Low
- LIXT $1.31
- RNAZ $2.66
- 52 Week High
- LIXT $4.40
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- LIXT 54.46
- RNAZ 30.32
- Support Level
- LIXT $2.25
- RNAZ $2.90
- Resistance Level
- LIXT $2.68
- RNAZ $3.50
- Average True Range (ATR)
- LIXT 0.23
- RNAZ 0.42
- MACD
- LIXT 0.01
- RNAZ 0.31
- Stochastic Oscillator
- LIXT 53.90
- RNAZ 50.74
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.